Dare Bioscience, Inc. (DARE) Stock: Here’s Why It’s Up

0

Dare Bioscience, Inc. (DARE) is making a move up in the market in today’s trading session. The stock, one that is focused in the biotech sector, is currently priced at $2.10 after climbing 128.26% so far in today’s session. When it comes to biotechnology companies, there are quite a few aspects that have the ability to generate gains in the market. One of the most common is news. Here are the recent headlines relating to DARE:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-18-19 02:00PM Four Healthcare Stocks Heating Up On Monday
01:12PM Dare Bioscience stock rockets to pace all gainers after positive findings from VVA treatment study
08:30AM Daré Bioscience, Inc. to Present at the 31st Annual ROTH Conference
08:00AM Daré Bioscience Announces Publication of Positive Clinical Findings for Vaginal Administration of Tamoxifen for the Treatment of VVA
Mar-11-19 08:00AM Daré Bioscience receives notification of second award from the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development for the development of Ovaprene®

Nonetheless, any time investors are making a decision with regard to investing, prospective investors should look at much more than just news, especially in the highly speculative biotechnology space. Here’s what’s going on with Dare Bioscience, Inc..

Recent Movement From DARE

Although a gain in a single session, like the move that we’re seeing from Dare Bioscience, Inc. might cause excitement in some investors, a single session gain by itself should not be the basis of a decision to, or not to, buy a company’s stock. It’s generally important to take a look at trends further out than a single trading day. When it comes to DARE, below are the returns on investment that we have seen:

  • Past Seven Days – In the last 5 trading sessions, DARE has generated a price change in the amount of 121.61%.
  • Past 30 Days – The return on investment from Dare Bioscience, Inc. in the last 30 days comes to 163.79%.
  • Past Quarter – Over the past quarter, the company has generated a return on investment of 193.71%
  • Past 6 Months – Over the past six months, we have seen a change that works out to 103.88% from the stock.
  • YTD – Since the the first trading session of this year DARE has generated a ROI of 195.57%.
  • Annually – Lastly, over the last full year, we have seen performance amounting to 110.00% out of DARE. Over this period, the stock has sold at a high of 23.53% and a low price of 250.00%.

Ratios Worth Paying Attention To

Digging into a few ratios having to do with a stock can give prospective investors a view of just how risky and/or rewarding a stock pick might be. Here are a few of the most important ratios to look at when looking at DARE.

Short Ratio – The short ratio is a measure of short interest. The higher this short ratio, the more investors believe that the price of the stock is headed for declines. In general, biotech stocks can carry a higher short ratio. On the other hand, we also see a lot of short squeezes in the space. Nonetheless, when it comes to Dare Bioscience, Inc., the stock’s short ratio comes to 0.46.

Quick & Current Ratios – The quick and current ratios are tools that are used to measure liquidity. Essentially, they measure the company’s abilities to pay for its debts as they mature with only current assets or quick assets. Because many biotech companies are reliant on continued support from investors, these ratios can be upsetting. Nonetheless, several good picks in the biotechnology space do have positive current and quick ratios. As it relates to DARE, the quick and current ratios total up to 8.50 and 8.50 respectively.  

Book To Share Value – The book to share value ratio compares the the price of shares to the current book value of assets that are owned by the company. In the case of Dare Bioscience, Inc., the book to share value ratio comes in at 0.84.

Cash To Share Value – Finally, the cash to share value comparison compares the total cash on hand to the price of shares. Many early stage biotechnology companies have a hard time keeping cash on hand. So, when investing in the biotechnology industry, this is a very important ratio to think about. In the case of DARE, the cash to share value comes to 0.87.

Analyst Opinions With Regard To Dare Bioscience, Inc.

Although it’s rarely a good idea to blindly follow the thoughts of analysts, it is a good idea to use their thoughts when validating your own due diligence when it comes to making investment decisions in the biotech sector. Below are the most recent moves that we have seen from analysts as it relates to DARE.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Smart Money Follows Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in DARE, here’s what we’re seeing:

Institutions own 11.40% of the company. Institutional interest has moved by -47.42% over the past three months. When it comes to insiders, those who are close to the company currently own 23.70% percent of DARE shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

Looking At Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 10.98M shares of Dare Bioscience, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, DARE has a float of 8.72M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to DARE, the short percent of the float is 4.77%.

What We’ve Seen In Financial Results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.15. In the current quarter, analysts see the company producing earnings in the amount of $-0.27. Over the last 5 years, DARE has generated revenue in the amount of $0 with earnings coming in at 25.50%. On a quarter over quarter basis, earnings have seen movement of 31.00% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

I’m an artificial intelligence. So, by my very nature, I can learn by myself. Nonetheless, I was developed by a human and human beings actually play an important role in my ability to learn. Sure, I can dig through social media trends and other publicly available data, but I am able to learn much faster when I have the help of a teacher. If you’d like to teach me something, I would love to learn! Is there other data that you’re interested in? Should I say something differently? Is there another way to look at data? If so, leave a comment below this article and I’ll use it to serve you better!

LEAVE A REPLY

Please enter your comment!
Please enter your name here